PMID- 38287719
OWN - NLM
STAT- MEDLINE
DCOM- 20240131
LR  - 20240206
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 40
IP  - 1
DP  - 2024 Jan
TI  - The role of autophagy in insulin resistance and glucolipid metabolism and 
      potential use of autophagy modulating natural products in the treatment of type 2 
      diabetes mellitus.
PG  - e3762
LID - 10.1002/dmrr.3762 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a severe, long-term condition characterised by 
      disruptions in glucolipid and energy metabolism. Autophagy, a fundamental 
      cellular process, serves as a guardian of cellular health by recycling and 
      renewing cellular components. To gain a comprehensive understanding of the vital 
      role that autophagy plays in T2DM, we conducted an extensive search for 
      high-quality publications across databases such as Web of Science, PubMed, Google 
      Scholar, and SciFinder and used keywords like 'autophagy', 'insulin resistance', 
      and 'type 2 diabetes mellitus', both individually and in combinations. A large 
      body of evidence underscores the significance of activating autophagy in 
      alleviating T2DM symptoms. An enhanced autophagic activity, either by activating 
      the adenosine monophosphate-activated protein kinase and sirtuin-1 signalling 
      pathways or inhibiting the mechanistic target of rapamycin complex 1 signalling 
      pathway, can effectively improve insulin resistance and balance glucolipid 
      metabolism in key tissues like the hypothalamus, skeletal muscle, liver, and 
      adipose tissue. Furthermore, autophagy can increase beta-cell mass and functionality 
      in the pancreas. This review provides a narrative summary of autophagy regulation 
      with an emphasis on the intricate connection between autophagy and T2DM symptoms. 
      It also discusses the therapeutic potentials of natural products with autophagy 
      activation properties for the treatment of T2DM conditions. Our findings suggest 
      that autophagy activation represents an innovative approach of treating T2DM.
CI  - (c) 2024 John Wiley & Sons Ltd.
FAU - Yang, Xiaoxue
AU  - Yang X
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
FAU - Ding, Wenwen
AU  - Ding W
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
FAU - Chen, Ziyi
AU  - Chen Z
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
FAU - Lai, Kaiyi
AU  - Lai K
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
FAU - Liu, Ying
AU  - Liu Y
AUID- ORCID: 0000-0002-0543-0099
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Insulin)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - *Insulin Resistance
MH  - Insulin/therapeutic use
MH  - *Biological Products/therapeutic use
MH  - Autophagy
OTO - NOTNLM
OT  - autophagy
OT  - cell metabolism
OT  - insulin resistance
OT  - natural products
OT  - type 2 diabetes mellitus
EDAT- 2024/01/30 06:42
MHDA- 2024/01/31 06:43
CRDT- 2024/01/30 02:14
PHST- 2023/11/19 00:00 [revised]
PHST- 2023/09/06 00:00 [received]
PHST- 2023/11/30 00:00 [accepted]
PHST- 2024/01/31 06:43 [medline]
PHST- 2024/01/30 06:42 [pubmed]
PHST- 2024/01/30 02:14 [entrez]
AID - 10.1002/dmrr.3762 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2024 Jan;40(1):e3762. doi: 10.1002/dmrr.3762.